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Abstract
Context: Cancer is a leading cause of death worldwide and novel chemotherapeutic agents with
better efficacy and safety profiles are much needed. Coumarins are natural polyphenolic
compounds with important pharmacological activities, which are present in many dietary
plants and herbal remedies.
Objectives: The objective of this study is to investigate natural and synthetic coumarin
derivatives with considerable anticancer capacity against three human cancer cell lines.
Materials and methods: We synthesized 27 coumarin derivatives (mostly having 4-methyl
moiety) and examined their cytotoxic effect on three human cancer cell lines, K562 (chronic
myelogenous leukemia), LS180 (colon adenocarcinoma), and MCF-7 (breast adenocarcinoma)
by MTT reduction assay. Screened compounds included 7-hydroxy-4-methylcoumarins
(7-HMCs), 7-acetoxy-4-methylcoumarins (7-AMCs), and different dihydroxy-4-methylcoumarin
(DHMC) and diacetoxy-4-methylcoumarin (DAMC) derivatives. Some compounds with methoxy,
amine, and bromine substitutions were also examined.
Results: 7,8-DHMCs bearing alkyl groups at C3 position were the most effective subgroup, and
of which, the most potent is compound 11, with an n-decyl chain at C3, which had IC50 values
of 42.4, 25.2, and 25.1 mM against K562, LS180, and MCF-7 cells, respectively. The second most
active subgroup was 7,8-DAMCs containing ethoxycarbonylmethyl and ethoxycarbonylethyl
moieties at C3 position. Compound 27 (6-bromo-4-bromomethyl-7-hydroxycoumarin), the
only derivative containing bromine also showed reasonable cytotoxic activities (IC50 range:
32.7–45.8 mM).
Discussion and conclusion: This structure–activity relationship (SAR) study of 4-methylcoumarins
shows that further investigation of these derivatives may lead to the discovery of novel
anticancer agents.
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Introduction
Cancer is a main cause of death around the world. It has
caused 7.6 million deaths in 2008 (13% of all mortalities) and
the estimates for 2030 are around 13.1 million (WHO, 2013).
Available chemotherapeutic agents have several drawbacks
including limited efficacy or high rate of adverse effects.
Therefore, searching for new anticancer drugs is of utmost
importance and could help to lower the health burden of this
devastating disease.
Coumarins possess a structure of fused benzene and
a-pyrone ring and belong to the large subclass of benzopyr-
ones that are widely found in several dietary plants. They are
present at high levels in cinnamon and many fruits and
vegetables (Krieger et al., 2013; Ribeiro da Silva et al., 2014).
Different derivatives of these compounds possess a wide
range of biological activities (Venugopala et al., 2013) such as
antioxidant (Morabito et al., 2010; Natella et al., 2010;
Pedersen et al., 2007), anti-inflammatory (Togna et al., 2014),
antimicrobial (Gupta et al., 2012), and in vitro (Macakova
et al., 2012) and in vivo platelet anti-aggregation effects
(Kathuria et al., 2012).
Plant-derived compounds have always provided an invalu-
able source for the discovery of novel anticancer agents
(Cufi et al., 2013; Jassbi et al., 2014). Natural coumarins, such
as osthole (Zhang et al., 2012), esculetin (Lee et al., 2013),
and umbelliferone (Weber et al., 1998) as well as several
coumarin containing plant extracts, have been reported
to inhibit the growth of cancer cells (Li et al., 2013;
Ngo et al., 2010).
We have previously synthesized several coumarin ana-
logues and have studied their biological potential (Goel et al.,
2007, 2009; Verma et al., 2011). Among the various
studied derivatives, 4-methylcoumarins were found to be
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of the highest interest. An advantageous property of
4-methylcoumarins is that due to the presence of a methyl
group at C4 position, they are less likely to be metabolized
to the mutagenic derivative 3,4-coumarin epoxide, by
the action of liver cytochrome P450 enzymes (Vassallo
et al., 2004). Furthermore, 4-methylcoumarins are assumed
to lack the anticoagulant effect of warfarin derivatives,
in which, the presence of the OH moiety at C4 is an
important feature for efficacy (Au & Rettie, 2008; Manolov
et al., 2006).
Cytotoxic effects of 4-methylcoumarin derivatives have
been evaluated against cancer cells (Goel et al., 2007, 2009;
Riveiro et al., 2008; Verma et al., 2011). In particular,
we have previously reported that 7,8-dihydroxy-4-
methylcoumarin (7,8-DHMC, 8) induces apoptosis in cancer
cells (Goel et al., 2007; Riveiro et al., 2008). Furthermore,
we have also observed that 7,8-diacetoxy-4-methylcoumarin
(7,8-DAMC, 14) and 7,8-diacetoxy-4-methylthiocoumarin
possess in vitro anticancer effect (Goel et al., 2009).
However, extensive studies on the structure–cytotoxic activity
of 4-methylcoumarins have not been performed yet.
In this study, we screened the anticancer potential of
synthesized 4-methylcoumarins with a major focus on 7,8-
DHMCs and 7,8-DAMCs derivatives against different solid
tumors and hematological malignancy cells and established a
structure–activity relationship (SAR) for these compounds.
Materials and methods
Reagents and chemicals
Fetal bovine serum (FBS), phosphate buffered saline (PBS),
RPMI 1640, and trypsin were purchased from Biosera
(Ringmer, UK). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT), umbelliferone and penicillin/
streptomycin were obtained from Sigma-Aldrich (St. Louis,
MO) and Invitrogen (San Diego, CA), respectively. Cisplatin
and doxorubicin were obtained from EBEWE Pharma
(Unterach, Austria) and dimethyl sulfoxide was purchased
from Merck (Darmstadt, Germany).
Chemistry
The C3 alkyl coumarins 1–3 and 9–11 were synthesized via
Pechmann condensation of 2-alkyl ethyl acetoacetate with
resorcinol/pyrogallol (Kathuria et al., 2009; Pechmann &
Duisberg, 1883). The 2-alkyl ethyl acetoacetate derivatives in
turn were obtained by alkylation of ethyl acetoacetate using
alkyl bromide and sodium hydride (Kathuria et al., 2009).
Compound 8 was synthesized by condensation of pyrogallol
and ethylacetoacetate in acidic conditions (Raj et al., 1996).
Compounds 4, 12, and 18 were synthesized by the reaction
of 2-acetylsuccinate with resorcinol, pyrogallol, and phlor-
oglucinol, respectively, under Pechmann conditions
(Chakravarti, 1935; Parmar et al., 1996). In a similar
manner, the compounds 5, 13, and 19 were obtained by
reaction of diethyl 2-acetylpentanedioate with resorcinol,
pyrogallol, and phloroglucinol, respectively (Li et al., 2012;
Parmar et al., 1987, 1996). The hydroxycoumarins 4, 5, 8, 12,
13, and 18 on acetylation with acetic anhydride/pyridine yield
the corresponding acetylated derivatives 6, 7, 14, 15, 16, and
20, respectively (Parmar et al., 1987, 1988, 1996; Raj et al.,
1996). Compound 17 was synthesized by methylation of
compound 12 using dimethyl sulfate and anhydrous potas-
sium carbonate (Raj et al., 1996). Compound 21 was isolated
according to the reported literature procedure (Sanchez-
Recillas et al., 2014). Compounds 22 and 23 were obtained
by the reaction of 1,2,4-trihydroxybenzene with diethyl
2-acetylsuccinate and diethyl 2-acetylpentanedioate, respect-
ively, followed by acetylation (Parmar et al., 1987).
Compound 24 was synthesized according to the synthetic
protocol established by our group (Aggarwal et al., 2012).
Compound 25 was synthesized by following the reported
multistep procedure and was then acetylated to yield
compound 26 (Reszka et al., 2010). To synthesize com-
pound 27, commercially available 4-bromoresorcinol was
reacted with ethyl-4-bromoacetoacetate via the literature
procedure (Bourbon et al., 2012). The compound 27 is
novel and the data are reported for the first time (Table 1).
The structures of all the synthesized compounds in this
study were unambiguously established on the basis of
comparing their melting point and NMR spectra with the
reported literature.
Cell lines
K562 (human chronic myelogenous leukemia), LS180
(human colon adenocarcinoma), and MCF-7 (human breast
adenocarcinoma) cells were obtained from the National Cell
Bank of Iran, Pasteur Institute, Tehran, Iran. These cell lines
represent some of the most common solid tumors and
hematological malignancies and have been used by several
authors for cytotoxicity assessments (Ash et al., 2014; Liu
et al., 2013; Ma et al., 2014). Cells were maintained at 37 C
in humidified air containing 5% CO2 and were grown in
monolayer cultures. All cell lines were maintained in RPMI
1640 supplemented with 10% FBS, and 100 units/mL
penicillin-G and 100 mg/mL streptomycin.
Cytotoxicity assay
Cell viability following exposure to synthetic compounds was
estimated by using the MTT reduction assay (Firuzi et al.,
2013; Mosmann, 1983). K562, LS180, and MCF-7 cells were
plated in 96-well microplates at densities of 40 000, 50 000,
and 30 000cells/mL, respectively (100mL per well). The
optimal densities were determined for each cell line based on
their growth curves and attention was paid to test the cells in
their exponential growth phase. After overnight incubation at
37 C, 3–4 different concentrations (ranging from 10 to
200 mM) of test compounds were added to wells in triplicate.
All the compounds were first dissolved in DMSO and then
diluted in the growth medium. The concentration of DMSO in
the wells did not exceed 0.5%. Cells were incubated further
for 72 h and then the medium was replaced with the RPMI
medium without phenol red containing 0.5 mg/mL of MTT.
Plates were incubated for another 4 h at 37 C, the media were
removed and formazan crystals formed in the cells were
dissolved in 200 mL of DMSO. The optical density was
measured at 570 nm with background correction at 655 nm
using a Bio-Rad microplate reader (Model 680, Bio-Rad,
Hercules, CA). The percent inhibition of viability for each
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concentration of the compound was calculated with reference
to the control and IC50 values were calculated with the
CurveExpert software version 1.34 for Windows (Sigma,
Saint Louis, MO). Each experiment was repeated 3–4 times
(Azizmohammadi et al., 2013; Miri et al., 2012).
Results and discussion
In this study, cytotoxic effects of 27 coumarin derivatives
(Table 1) were studied against three human cancer cell lines,
i.e., K562 (human chronic myelogenous leukemia), LS180
(human colon adenocarcinoma), and MCF-7 (human breast
adenocarcinoma) cells (Table 2) and SAR study of the test
compounds was examined.
In general, 4-methylcoumarin derivatives had similar
effects on three types of cancer cells. 7,8-DHMCs, 8–13,
were observed to be the most active compounds. In particular,
compounds 9–11 exhibited IC50 values of less than 100 mM in
all the cell lines studied, and among these, compound 11 was
found to be the most potent derivative. This derivative had the
lowest IC50 values against LS180 and MCF-7 cell lines and
the second lowest IC50 value against K562 cells (after
compound 10). Thus, the presence of two hydroxyl groups at
C7 and C8 positions seem to improve the potency of
methylcoumarins as cytotoxic agents. Derivatives with IC50
values of higher than 200 mM were considered inactive.
Umbelliferone (7-hydroxycoumarin), a natural coumarin
compound, was also tested for comparison with synthesized
Table 1. Structures of cytotoxic coumarin derivatives screened against cancer cell lines.
Structures Substitutions References
O O
R2
OR1
R1 R2
1 H CH2CH3 Kathuria et al. (2009)
2 H n-C6H13 Kathuria et al. (2009)
3 H n-C10H21 Kathuria et al. (2009)
4 H CH2CO2Et Parmar et al. (1996)
5 H CH2CH2CO2Et Li et al. (2012)
6 Ac CH2CO2Et Raj et al. (1996)
7 Ac CH2CH2CO2Et Parmar et al. (1988)
R3
OR2
OR1
O O
R1 R2 R3
8 H H H Parmar et al. (1996)
9 H H C2H5 Kathuria et al. (2009)
1 H H n-C6H13 Kathuria et al. (2009)
11 H H n-C10H21 Kathuria et al. (2009)
12 H H CH2CO2Et Chakravarti (1935)
13 H H CH2CH2CO2Et Parmar et al. (1987)
14 Ac Ac H Parmar et al. (1996)
15 Ac Ac CH2CO2Et Parmar et al. (1988)
16 Ac Ac CH2CH2CO2Et Parmar et al. (1987)
17 Me Me CH2CO2Et Raj et al. (1996)
R3
OR2
R1O O O
R1 R2 R3
18 H H CH2CO2Et Parmar et al. (1988)
19 H H CH2CH2CO2Et Parmar et al. (1987)
20 Ac Ac CH2CO2Et Raj et al. (1996)
R2
R1
O OAcO
AcO
R1 R2
21 H H Sanchez-Recillas et al. (2014)
22 Me CH2CO2Et Parmar et al. (1987)
23 Me CH2CH2CO2Et Parmar et al. (1987)
R2
R1HN O O
R1 R2
24 H Me Aggarwal et al. (2012)
25 H n-C3H7 Reszka et al. (2010)
26 Ac n-C3H7 Reszka et al. (2010)
O OHO
Br
Br
27 Mp: 251–252 C. 1H NMR (400 MHz, DMSO-d6)
 4.84 (s, 2H, CH2Br),
6.51 (s, 1H, H-3), 6.89 (s, 1H, H-8), 7.99 (s, 1H),
11.56 (br, 1H, OH)
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4-methylcoumarin derivatives and it did not show any
cytotoxic effect on the tested cell lines. None of the
compounds was more potent than the standard chemother-
apeutic agents, cisplatin and doxorubicin (Table 2).
The finding that 7-hydroxy-4-methylcoumarins (7-HMCs)
were less potent than their corresponding dihydroxy ana-
logues, i.e., 7,8-DHMC (e.g., compound 1 versus compound
9, etc.) has also been observed previously for the antioxidant
capacity of these compounds by our research groups
(Kancheva et al., 2010; Pedersen et al., 2007).
It has been previously shown by us and other investigators
that compound 8 induces apoptosis in human cancer cell lines
of hematological malignancies, HL-60 and U-937 (Goel et al.,
2007; Riveiro et al., 2008). However, this derivative was
reported to be effective only at doses higher than 100 mM,
which is in agreement with our present observations.
A previous SAR study that has examined the effect
of coumarins on U-937 leukemic cells have shown that
o-dihydroxy coumarins show selective toxicity towards cancer
cells (Va´zquez et al., 2012). Another report has shown that
7,8-DHMC is a potent anticancer agent that selectively targets
leukemia cells (Va´zquez et al., 2013).
Substitution of the hydroxyl group with an acetoxy group
reduced the cytotoxic activity, as revealed by the comparison
of compounds 4, 5, 8, and 25 with compounds 6, 7, 14, and
26, respectively. A similar phenomenon was observed when
the hydrogen was replaced with methyl moiety (12 versus 17).
On the contrary, comparison of derivatives 12 and 13 with 15
and 16 shows an enhancement of the cytotoxic activity with
the introduction of acetoxy group, although the change is not
substantial.
With regard to the effect of C3 alkyl moiety on the
cytotoxic activity in 7-HMCs, replacement of ethyl (1) with n-
hexyl (2) and n-decyl (3) chains improved the activity against
all three cell lines and it appeared to be dependent on the size
of the alkyl chain (compound 3 with n-decyl chain is more
active than compound 2 with n-hexyl chain). A similar
situation was also observed in 7,8-DHMCs when compound 8
(with hydrogen at C3 position) was compared with com-
pounds 9, 10, and 11 (with ethyl, n-hexyl, and n-decyl chains
at C3 position, respectively). Among 7,8-DHMC derivatives,
the longer the alkyl chain, the higher was the activity
(compounds 11, 10, and 9, in decreasing order of efficiency).
This effect of the alkyl group on the cytotoxicity is
presumably due to the enhanced lipophilicity of the longer
alkyl chains that consequently enhances cell membrane
penetration ability of the test compounds (Mannhold et al.,
2008; Zavrsˇnik et al., 2003).
Introduction of an ester moiety at position C3 is not helpful
in increasing the cytotoxicity of either 7-HMCs (compounds 4
and 5) or 7,8-DHMCs (compounds 12 and 13) in comparison
with an alkyl chain substitution. Thus, it appears that by a
careful modification of the structure of these compounds,
finding more potent anticancer agents is possible.
We had previously observed that 7,8-diacetoxy-4-methyl-
coumarin (compound 14) and 7,8-diacetoxy-4-methylthiocou-
marin possess cytotoxic effects (Goel et al., 2007). In the
present report, we observed that 7,8-DAMCs 15 and 16,
bearing ethoxycarbonylmethyl and ethoxycarbonylethyl moi-
eties at C3 position, respectively, have improved potency
compared with the compound 14 (with an H at C3) in K562
and MCF-7 cell lines, but not in LS180 cells.
Compounds containing two hydroxyl moieties at C5 and
C7 positions (compounds 18 and 19) had lower potencies in
comparison with the derivatives with hydroxyl moieties at C7
and C8 positions (compounds 8–13). This can probably be
explained by the strong effect that can be brought about by the
presence of the catechol moiety (Foti et al., 2005).
Another interesting compound (27) that showed good
activity in all the cell lines has bromo groups substituted at C4
and C6 positions. The rest of the compounds including those
bearing amine and amide moieties at C7 position (compounds
24, 25, and 26) were not very active against any of the cell
lines.
Several studies have examined the mechanism of antic-
ancer action of different coumarin derivatives and have shown
that these compounds can induce apoptosis and also inhibit
cell-cycle progression (Chen et al., 2012; Haghighi et al.,
2014; Singh et al., 2011). Many of these reports have shown
that coumarins up-regulate proapoptotic factors, while they
down-regulate anti-apoptotic markers in cancer cells (Arbab
et al., 2012; Rubio et al., 2014; Singh et al., 2011),
mechanisms that could plausibly apply also to our studied
methylcoumarin derivatives. For instance, it has been shown
that dentatin, a natural coumarin, induces apoptosis in
prostate cancer cells mediated by down-regulation of anti-
apoptotic proteins (Bcl-2, Bcl-xL, and survivin), disruption of
mitochondrial membrane potential, and also NF-kB inhibition
Table 2. Cytotoxicity of 4-methylcoumarin derivatives against different
human cancer cell lines.
IC50 (mM)
Compounds K562 LS180 MCF-7
1 111.0 ± 28.4 4200 189.8 ± 23.6
2 90.7 ± 14.2 59.4 ± 11.9 110.5 ± 1.3
3 66.7 ± 13.7 43.8 ± 5.8 66.6 ± 1.6
4 4200 4200 89.8 ± 8.3
5 4200 4200 198.6 ± 34.5
6 4200 4200 4200
7 4200 4200 4200
8 138.7 ± 75.0 4200 98.4 ± 12.2
9 51.0 ± 14.7 67.7 ± 3.0 78.2 ± 5.6
10 40.8 ± 10.6 67.1 ± 20.8 61.3 ± 7.9
11 42.4 ± 19.6 25.2 ± 1.6 25.1 ± 2.8
12 68.0 ± 8.9 175.2 ± 34.2 131.3 ± 20.0
13 62.8 ± 23.5 4200 90.4 ± 22.5
14 4200 86.4 ± 22.8 152.6 ± 11.0
15 85.3 ± 15.7 92.0 ± 18.9 88.9 ± 3.9
16 70.7 ± 8.9 137.7 ± 11.2 72.7 ± 8.8
17 4200 4200 4200
18 165.7 ± 65.5 4200 4200
19 4200 4200 139.1 ± 6.9
20 163.3 ± 59.0 4200 183.5 ± 4.1
21 114.9 ± 57.1 57.2 ± 2.4 61.9 ± 17.6
22 70.2 ± 19.9 94.7 ± 22.4 88.0 ± 7.0
23 117.1 ± 6.2 4200 92.5 ± 22.2
24 4200 4200 4200
25 4200 154.1 ± 25.0 107.8 ± 17.7
26 4200 4200 4200
27 45.8 ± 4.8 49.0 ± 1.8 32.7 ± 1.5
Umbelliferone 4200 4200 4200
Cisplatin 5.3 ± 1.8 10.0 ± 1.7 11.9 ± 1.9
Doxorubicin 0.065 ± 0.015 0.031 ± 0.007 0.053 ± 0.013
Values represent the mean ± S.E.M. of 3–5 experiments.
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(Arbab et al., 2012). In another report, RKS262, a coumarin
derivative, has shown to induce apoptosis by reduction
of mitochondrial membrane depolarization potential,
up-regulation of pro-apoptotic markers (Bid, Bad, and Bok),
and down-regulation of pro-survival factors (Bcl-xl and Mcl-
1) (Singh et al., 2011). Other investigators have demonstrated
that 7-isopentenyloxycoumarin induces cell-cycle arrest at the
G2/M stage in bladder cancer cells (Haghighi et al., 2014).
Conclusions
In this study, cytotoxic effects of 27 coumarin derivatives
were tested against three human cancer cell lines and some
of the derivatives showed promising anticancer activities.
The screened derivatives included 7-HMC, 7,8-DHMC, 7-
acetoxy-4-methylcoumarin (7-AMC), and 7,8-DAMC, among
others. It was observed that 7,8-DHMC derivatives, followed
by 7,8-DAMCs, were the most potent anticancer agents.
Insertion of long alkyl moiety at C3 position generally
improved the anticancer activity, probably due to the
enhancement of lipophilicity and cell penetration ability.
These SAR studies show that the investigation of different
derivatives of 4-methylcoumarins may lead to the discovery
of novel more efficient anticancer agents.
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